Menu

Duke Sued for Millions over Fraudulent Data

A lawsuit claims that Duke University and biologist Erin Potts-Kant used bad data in projects funded by dozens of government grants.

Sep 6, 2016
Jef Akst

FLICKR, PENSDEVILSixty grants worth some $200 million—that’s what biologist Joseph Thomas claims is affected by fraudulent data from Duke University and biologist Erin Potts-Kant, Thomas’s former supervisor, ScienceInsider and Retraction Watch reported last week (September 1). And the university may have to shell out three times that amount if Thomas’s lawsuit is successful.

The Duke case “should scare all [academic] institutions around the country,” attorney Joel Androphy of Berg & Androphy told Retraction Watch. If successful, he added, it could “open the floodgates” to other whistleblowing cases on research misconduct in academia.

Potts-Kant was arrested on charges of embezzlement (totaling more than $25,000) in March 2013. She pled guilty, received a fine and probation, and was ordered to perform community service. Following a Duke investigation, 15 of Potts-Kant’s papers were retracted, some citing “unreliable” data. Additional publications have corrections or expressions of concern.

The lawsuit filed by Thomas was unsealed by a US district court last month, according to the news report; in it, Thomas claims that other researchers at Duke were aware of the problems with Pott-Kant’s work but that the university withheld information from federal funding agencies.

According to Thomas’s complaint, the misconduct affects at least 49 grants worth $82.8 million from federal agencies such as the National Institutes of Health (NIH) and the Environmental Protection Agency, and that an additional 15 NIH grants, worth $120.9 million, were awarded based on fraudulent data.

Duke responded to the accusations in a statement: “Even though the full scope of Ms. Potts-Kant’s actions were not known at the time, Duke notified several government agencies in June 2013 about the matter and immediately launched a formal scientific misconduct investigation, as required by federal law.”

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.

Thermo Fisher Scientific: Freezers for Biological Samples

Thermo Fisher Scientific: Freezers for Biological Samples

Fluctuations in temperature can reduce the efficacy, decompose, or shorten the shelf life of biologics. Therefore, it is important to store biologics at the right temperature using standardized protocols.